Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

• Status: Terminated
• Trial end date: 2018-06-08
• Target enrollment: 0
• Participant gender: All

Summary

This study compares the bioavailability of IV and PO acetaminophen in both blood and the cerebrospinal fluid (CSF) of patients following subarachnoid hemorrhage. The study will also compare the temperature and levels of inflammatory cytokines in both blood and CSF of patients treated with IV and PO acetaminophen.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Treatments: Acetaminophen; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Diagnosis of subarachnoid hemorrhage (must be confirmed by CT, CT angiography, lumbar puncture, or MRI).

• Fisher Grade between 1-3 (subarachnoid blood without signs of intraventricular hemorrhage or parenchymal extension).

• Placement of an external ventricular drain.

• Adults aged 18-100 years.

Exclusion Criteria:

• Anyone under the age of 18 or over the age of 100.

• Adult patients with subarachnoid hemorrhage with interventricular hemorrhage or parenchymal extension (Fisher Grade 4).

• Contraindication to acetaminophen such as a known hypersensitivity, severe hepatic impairment, or severe active liver disease.

• Severe renal impairment (creatinine clearance ≤ 30 mL/min).